Arming the Patient's Immune System to Fight Cancer

Targovax is a clinical stage immuno-oncology company dedicated to the development of highly targeted immunotherapies for cancer patients.

Targovax is developing two complementary and highly targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. Both treatment approaches harness the patient’s own immune system to fight the cancer.

Read more on targeting cancer cells with engineered oncolytic viruses

Read more on targeting RAS mutations

Targovax’s lead neo-antigen targeted immunotherapy, TG01, is a therapeutic cancer vaccine against RAS mutated cancers. TG01 is currently in a Phase I/II clinical trial in resected pancreatic cancer. In the Phase I part of the study, TG01 induced mutant RAS specific T cell immune responses in almost all patients and had a favorable safety and tolerability profile. Encouraging top line two-year survival data showed that 13 out of 19 evaluable patients were still alive after two years. This contrasts favorably with a historical 2-year overall survival rate of 30-53%. The trial is fully recruited (32 patients in total). Final 2 year OS results for all patients are expected in 2018. 

TG02,  the company’s second generation cancer vaccine, is being investigated in the first time in man clinical phase Ib study in colorectal cancer. The safety review of the first patients showed no issues.

ONCOS-102 is Targovax’s lead oncolytic adenovirus-based pipeline product – a purposefully engineered human serotype 5 adenovirus optimized to induce systemic anti-tumor T cell response in cancer patients. ONCOS-102 has completed a Phase I clinical study and two new phase I/II trials have stared, one in malignant melanoma and one in mesothelioma. The initial planned safety reviews in the first treated patients in both trials has been completed without any safety concerns.

ONCOS-102 showed encouraging Phase I efficacy data in a challenging patient population. In its Phase I clinical trial in heavily-pretreated patients with multiple types of solid tumors, ONCOS-102 demonstrated a stable disease (SD) rate of 40% in 10 evaluable patients. ONCOS-102 has shown to lead to a strong activation of the immune system against the cancer, which was correlated with survival.

Targovax has Orphan Drug Designation with the FDA and EMA for TG01 in pancreatic cancer and for ONCOS-102 in mesothelioma, ovarian cancer and soft tissue sarcoma.

Targovax remains committed to the discovery, development and delivery to patients of its first-in-class targeted immunotherapies.


Targovax is developing its lead mutRAS neo-antigen cancer vaccine, TG01, in a Phase 1/2 clinical trial in resected pancreatic cancer. Targovax’s other RAS targeting neo-antigen vaccine, TG02, has entered a Phase 1 clinical trial in combination with the immune checkpoint inhibitor Keytruda in colorectal cancer. Targovax’s lead adenoviral candidate, ONCOS-102, has successfully completed a Phase 1 study in solid tumors. It is further being trialed in immune-checkpoint refractory melanoma, in mesothelioma, and in ovarian, colorectal, and prostate cancers.

Targovax is interested in discussing various forms of strategic collaboration regarding its projects.